Edwards Lifesciences Corp. (EW)

$70.38

+0.84

(+1.21%)▲

Market is closed - opens 8 PM, 22 Nov 2024

Performance

  • $68.59
    $70.38
    $70.38
    downward going graph

    2.55%

    Downside

    Day's Volatility :2.55%

    Upside

    0.0%

    downward going graph
  • $58.93
    $96.12
    $70.38
    downward going graph

    16.27%

    Downside

    52 Weeks Volatility :38.69%

    Upside

    26.78%

    downward going graph

Returns

PeriodEdwards Lifesciences Corp.Sector (Health Care)S&P500
3 Months
-2.47%
-7.7%
6.2%
6 Months
-22.91%
-2.5%
11.5%
1 Year
3.7%
9.5%
29.9%
3 Years
-39.45%
7.9%
26.4%

Highlights

Market Capitalization
41.4B
Book Value
$16.18
Earnings Per Share (EPS)
2.57
PE Ratio
27.06
PEG Ratio
6.44
Wall Street Target Price
76.391
Profit Margin
65.86%
Operating Margin TTM
29.11%
Return On Assets TTM
10.65%
Return On Equity TTM
19.14%
Revenue TTM
6.3B
Revenue Per Share TTM
10.5
Quarterly Revenue Growth YOY
8.9%
Gross Profit TTM
4.3B
EBITDA
2.1B
Diluted Eps TTM
2.57
Quarterly Earnings Growth YOY
7.16
EPS Estimate Current Year
2.53
EPS Estimate Next Year
2.47
EPS Estimate Current Quarter
0.64
EPS Estimate Next Quarter
0.62

Analyst Recommendation

Buy
    60%Buy
    35%Hold
    5%Sell
Based on 40 Wall street analysts offering stock ratings for Edwards Lifesciences Corp.(by analysts ranked 0 to 5 stars)
Based on 40 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
24
24
22
Hold
14
13
15
Sell
2
2
2

Analyst Forecast

What analysts predicted

Upside of 8.54%

Current $70.38
Target $76.39

Company Financials

FY18Y/Y Change
Revenue
3.7B
↑ 8.37%
Net Income
722.2M
↑ 16.09%
Net Profit Margin
19.4%
↑ 1.29%
FY19Y/Y Change
Revenue
4.3B
↑ 16.79%
Net Income
1.0B
↑ 44.96%
Net Profit Margin
24.08%
↑ 4.68%
FY20Y/Y Change
Revenue
4.4B
↑ 0.88%
Net Income
823.4M
↓ 21.35%
Net Profit Margin
18.77%
↓ 5.31%
FY21Y/Y Change
Revenue
5.2B
↑ 19.29%
Net Income
1.5B
↑ 82.55%
Net Profit Margin
28.73%
↑ 9.96%
FY22Y/Y Change
Revenue
5.4B
↑ 2.86%
Net Income
1.5B
↑ 1.25%
Net Profit Margin
28.28%
↓ 0.45%
FY23Y/Y Change
Revenue
6.0B
↑ 11.56%
Net Income
1.4B
↓ 7.85%
Net Profit Margin
23.35%
↓ 4.93%
Q2 FY23Q/Q Change
Revenue
1.5B
↑ 4.84%
Net Income
307.1M
↓ 9.81%
Net Profit Margin
20.07%
↓ 3.26%
Q3 FY23Q/Q Change
Revenue
1.5B
↓ 3.22%
Net Income
384.9M
↑ 25.33%
Net Profit Margin
25.99%
↑ 5.92%
Q4 FY23Q/Q Change
Revenue
1.5B
↑ 3.59%
Net Income
369.9M
↓ 3.9%
Net Profit Margin
24.11%
↓ 1.88%
Q1 FY24Q/Q Change
Revenue
1.6B
↑ 4.18%
Net Income
351.9M
↓ 4.87%
Net Profit Margin
22.02%
↓ 2.09%
Q2 FY24Q/Q Change
Revenue
1.4B
↓ 13.28%
Net Income
366.3M
↑ 4.09%
Net Profit Margin
26.43%
↑ 4.41%
Q3 FY24Q/Q Change
Revenue
1.4B
↓ 2.27%
Net Income
3.1B
↑ 738.33%
Net Profit Margin
226.73%
↑ 200.3%
FY18Y/Y Change
Total Assets
5.3B
↓ 6.54%
Total Liabilities
2.2B
↓ 19.19%
FY19Y/Y Change
Total Assets
6.5B
↑ 21.87%
Total Liabilities
2.3B
↑ 7.17%
FY20Y/Y Change
Total Assets
7.2B
↑ 11.54%
Total Liabilities
2.7B
↑ 13.8%
FY21Y/Y Change
Total Assets
8.5B
↑ 17.49%
Total Liabilities
2.7B
↑ 0.15%
FY22Y/Y Change
Total Assets
8.3B
↓ 2.47%
Total Liabilities
2.5B
↓ 6.78%
FY23Y/Y Change
Total Assets
9.4B
↑ 12.91%
Total Liabilities
2.6B
↑ 6.36%
Q2 FY23Q/Q Change
Total Assets
9.0B
↑ 4.08%
Total Liabilities
2.6B
↓ 1.22%
Q3 FY23Q/Q Change
Total Assets
9.4B
↑ 4.07%
Total Liabilities
2.6B
↑ 3.37%
Q4 FY23Q/Q Change
Total Assets
9.4B
↓ 0.08%
Total Liabilities
2.6B
↑ 0.0%
Q1 FY24Q/Q Change
Total Assets
9.7B
↑ 3.98%
Total Liabilities
2.5B
↓ 3.55%
Q2 FY24Q/Q Change
Total Assets
10.1B
↑ 3.73%
Total Liabilities
2.6B
↑ 1.76%
Q3 FY24Q/Q Change
Total Assets
13.0B
↑ 28.44%
Total Liabilities
3.4B
↑ 29.49%
FY18Y/Y Change
Operating Cash Flow
926.8M
↓ 7.38%
Investing Cash Flow
76.7M
↓ 111.85%
Financing Cash Flow
-1.1B
↑ 132.71%
FY19Y/Y Change
Operating Cash Flow
1.2B
↑ 27.26%
Investing Cash Flow
-595.8M
↓ 876.79%
Financing Cash Flow
-115.6M
↓ 89.5%
FY20Y/Y Change
Operating Cash Flow
1.1B
↓ 10.61%
Investing Cash Flow
-531.1M
↓ 10.86%
Financing Cash Flow
-486.9M
↑ 321.19%
FY21Y/Y Change
Operating Cash Flow
1.7B
↑ 64.29%
Investing Cash Flow
-1.7B
↑ 224.33%
Financing Cash Flow
-356.3M
↓ 26.82%
FY22Y/Y Change
Operating Cash Flow
1.2B
↓ 29.67%
Investing Cash Flow
252.3M
↓ 114.65%
Financing Cash Flow
-1.6B
↑ 344.71%
Q2 FY23Q/Q Change
Operating Cash Flow
33.6M
↓ 89.3%
Investing Cash Flow
70.2M
↑ 13940.0%
Financing Cash Flow
52.1M
↓ 125.22%
Q3 FY23Q/Q Change
Operating Cash Flow
411.5M
↑ 1124.7%
Investing Cash Flow
159.7M
↑ 127.49%
Financing Cash Flow
-143.3M
↓ 375.05%

Technicals Summary

Sell

Neutral

Buy

Edwards Lifesciences Corp. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-0.73%
-22.91%
3.7%
-39.45%
-13.36%
Stryker Corporation
Stryker Corporation
5.37%
14.98%
31.16%
48.17%
91.32%
Boston Scientific Corp.
Boston Scientific Corp.
2.45%
19.64%
62.67%
121.55%
115.46%
Abbott Laboratories
Abbott Laboratories
-0.91%
10.6%
12.88%
-7.45%
38.44%
Medtronic Plc
Medtronic Plc
-7.69%
-1.92%
7.32%
-28.04%
-24.1%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
27.1
27.06
6.44
2.53
0.19
0.11
NA
16.18
Stryker Corporation
Stryker Corporation
41.85
41.66
2.71
12.05
0.19
0.07
0.01
52.86
Boston Scientific Corp.
Boston Scientific Corp.
71.89
74.65
1.64
2.46
0.09
0.05
NA
14.05
Abbott Laboratories
Abbott Laboratories
35.67
35.6
2.28
4.68
0.15
0.06
0.02
22.94
Medtronic Plc
Medtronic Plc
29.55
29.55
1.63
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$41.4B
-13.36%
27.1
65.86%
Stryker Corporation
Stryker Corporation
Buy
$148.7B
91.32%
41.85
16.34%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$128.2B
115.46%
71.89
11.26%
Abbott Laboratories
Abbott Laboratories
Buy
$203.6B
38.44%
35.67
13.99%
Medtronic Plc
Medtronic Plc
Buy
$110.3B
-24.1%
29.55
12.06%

Insights on Edwards Lifesciences Corp.

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 1.59B → 1.35B (in $), with an average decrease of 7.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, 351.9M → 3.07B (in $), with an average increase of 46.0% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 62.7% return, outperforming this stock by 59.0%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 121.5% return, outperforming this stock by 160.9%

Institutional Holdings

  • Vanguard Group Inc

    10.61%

  • BlackRock Inc

    8.64%

  • State Street Corp

    4.41%

  • AllianceBernstein L.P.

    3.45%

  • Bank of New York Mellon Corp

    3.35%

  • Wellington Management Company LLP

    2.87%

Company Information

edwards lifesciences (nyse: ew) is the global leader in the science of heart valves and hemodynamic monitoring. driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that save and enhance lives. headquartered in irvine, california, edwards lifesciences has extensive operations in north america, europe, japan, latin america and asia and currently employs about 6,400 individuals worldwide. for us, helping patients is not a slogan – it's our life’s work. from developing devices that replace or repair a diseased heart valve to creating new technologies that monitor vital signs in the critical care setting, we help ensure that patients regain and even improve their quality of life.

Organization
Edwards Lifesciences Corp.
Employees
19800
CEO
Mr. Bernard J. Zovighian
Industry
Health Technology

FAQs